The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2016Small-molecule Inhibitor to Stop Alpha-synuclein Spread for the Treatment of Parkinson's Disease
Study Rationale:
The hypothesis that misfolded alpha-synuclein (a protein associated with Parkinson's) aggregates (clumps) move from neuron-to-neuron is gaining widespread acceptance as a central... -
Research Grant, 2017White Blood Cell and Urine Collection in LRRK2 and GBA Mutation Carriers
Study Rationale:
Mutations in the LRRK2 and GBA genes increase the risk for Parkinson's disease (PD). The mechanism by which these mutations increase PD risk is unknown. One potential explanation may...
-
Therapeutic Pipeline Program, 2017Small-Molecule Pharmacological Chaperones Reverse Alpha-synuclein-impaired Debris Removal
Study Rationale:
The goal of this project is to find therapeutic drugs for Parkinson's disease (PD) that target alpha-synuclein, a key player in PD. We propose that the negative impact of alpha...
-
Improved Biomarkers and Clinical Outcome Measures, 2016Developing New Method for GBA sequencing and Detection of Germ-line or Somatic Point Mutations, Deletion/Insertions and Recombinations with the GBA Pseudo Gene
Study Rationale:
Mutations in the GBA gene are the most common genetic cause of Parkinson’s disease. This gene has a nearby pseudogene, which is a genetic material that is very...
-
Research Grant, 2016Planning Phase for a Phase IIa Study of Nilotinib in People with Parkinson's Disease
Study Rationale:
Nilotinib, a drug approved for chronic myelogenous leukemia, inhibits the protein c-Abl. Higher brain levels of c-Abl are associated with Parkinson's disease (PD), and laboratory...
-
Therapeutic Pipeline Program, 2016Small Molecule Inhibitors of C-Abl for Parkinson's Disease Modification
Study Rationale:
Abelson tyrosine kinase (c-Abl) is believed to drive the deleterious events leading to loss of dopamine neurons in people with Parkinson's disease. This project will identify small...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.